Swedish Contrast Media Company Starts Clinical Phase III Studies With New Agent for MR Imaging of the Liver
6th Oct 2005, 16:13 GMT
CMC Contrast AB Starts Clinical Phase III Studies on New Promising Contrast Medium for Scanning of Liver Tumours by Means of MRI.
Swedish Contrast Media Company Starts Clinical Phase III Studies With New Agent for MR Imaging of the Liver related news:
- Swedish Contrast Media Company Starts Clinical Phase III Studies With New Agent for MR Imaging of the Liver — PR Newswire: All Releases
- Melanoma clinical trial discontinued — OnMedica Latest News
- Market Pulse: CancerVax, Serono to discontinue Phase III Canvaxin trial — Financial News News from StratCenter.com
- Chiron and Nektar Announce Initiation of Phase III Clinical Program Evaluating Tobramycin Inhalation Powder in Cystic Fibrosis Patients 1st of 2 Pivotal Trials Begins, 2nd Planned for 2006 — Bio-Technology News from StratCenter.com
- Serono: Data And Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients With Stage III Melanoma — PR Newswire: All Releases
- Market Pulse: Human Genome unsure it will proceed with Phase III trial — Financial News News from StratCenter.com
- Epix, Schering Get EU Vasovist OK — Financial News News from StratCenter.com
- Spectral Imaging III — PhysicsWeb Events
- Data and Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients with Stage III Melanoma — Newsticker - WELT.de
- AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis — Japan Corporate News
Latest news from Angiography/ Cardiac Cath News from StratCenter.com:
- Thinking Systems Releases Enhanced PET-CT Functions for Its ThinkingPACS
- Tallahassee Memorial Hospital at the Forefront in Treatment of Heart Attack Patients
- Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease